vs

Side-by-side financial comparison of American Assets Trust, Inc. (AAT) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $110.6M, roughly 1.4× American Assets Trust, Inc.). American Assets Trust, Inc. runs the higher net margin — 6.1% vs -5.5%, a 11.6% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 1.8%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -0.1%).

Personal Assets Trust is a large British investment trust. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The chairman is Iain Ferguson CBE.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

AAT vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.4× larger
TARS
$151.7M
$110.6M
AAT
Growing faster (revenue YoY)
TARS
TARS
+126.6% gap
TARS
128.4%
1.8%
AAT
Higher net margin
AAT
AAT
11.6% more per $
AAT
6.1%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-0.1%
AAT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AAT
AAT
TARS
TARS
Revenue
$110.6M
$151.7M
Net Profit
$6.7M
$-8.4M
Gross Margin
Operating Margin
23.4%
-5.3%
Net Margin
6.1%
-5.5%
Revenue YoY
1.8%
128.4%
Net Profit YoY
-16.3%
63.8%
EPS (diluted)
$0.08
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AAT
AAT
TARS
TARS
Q1 26
$110.6M
Q4 25
$110.1M
$151.7M
Q3 25
$109.6M
$118.7M
Q2 25
$107.9M
$102.7M
Q1 25
$108.6M
$78.3M
Q4 24
$113.5M
$66.4M
Q3 24
$122.8M
$48.1M
Q2 24
$110.9M
$40.8M
Net Profit
AAT
AAT
TARS
TARS
Q1 26
$6.7M
Q4 25
$-8.4M
Q3 25
$4.5M
$-12.6M
Q2 25
$5.5M
$-20.3M
Q1 25
$42.5M
$-25.1M
Q4 24
$-23.1M
Q3 24
$16.7M
$-23.4M
Q2 24
$11.9M
$-33.3M
Gross Margin
AAT
AAT
TARS
TARS
Q1 26
Q4 25
59.4%
Q3 25
60.5%
Q2 25
62.6%
Q1 25
62.0%
Q4 24
61.3%
Q3 24
65.5%
Q2 24
63.6%
Operating Margin
AAT
AAT
TARS
TARS
Q1 26
23.4%
Q4 25
21.1%
-5.3%
Q3 25
22.6%
-12.2%
Q2 25
24.1%
-21.6%
Q1 25
66.3%
-33.5%
Q4 24
26.5%
-36.8%
Q3 24
30.8%
-52.3%
Q2 24
27.8%
-81.6%
Net Margin
AAT
AAT
TARS
TARS
Q1 26
6.1%
Q4 25
-5.5%
Q3 25
4.1%
-10.6%
Q2 25
5.1%
-19.8%
Q1 25
39.2%
-32.1%
Q4 24
-34.8%
Q3 24
13.6%
-48.7%
Q2 24
10.7%
-81.6%
EPS (diluted)
AAT
AAT
TARS
TARS
Q1 26
$0.08
Q4 25
$0.06
$-0.17
Q3 25
$0.07
$-0.30
Q2 25
$0.09
$-0.48
Q1 25
$0.70
$-0.64
Q4 24
$0.14
$-0.57
Q3 24
$0.28
$-0.61
Q2 24
$0.20
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AAT
AAT
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$118.3M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.1B
$343.4M
Total Assets
$2.9B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AAT
AAT
TARS
TARS
Q1 26
$118.3M
Q4 25
$129.4M
$417.3M
Q3 25
$138.7M
$401.8M
Q2 25
$143.7M
$381.1M
Q1 25
$143.9M
$407.9M
Q4 24
$425.7M
$291.4M
Q3 24
$533.0M
$317.0M
Q2 24
$114.9M
$323.6M
Total Debt
AAT
AAT
TARS
TARS
Q1 26
Q4 25
$1.7B
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$2.0B
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
AAT
AAT
TARS
TARS
Q1 26
$1.1B
Q4 25
$1.2B
$343.4M
Q3 25
$1.2B
$335.1M
Q2 25
$1.2B
$332.6M
Q1 25
$1.2B
$342.5M
Q4 24
$1.2B
$224.5M
Q3 24
$1.2B
$237.5M
Q2 24
$1.2B
$252.2M
Total Assets
AAT
AAT
TARS
TARS
Q1 26
$2.9B
Q4 25
$2.9B
$562.2M
Q3 25
$2.9B
$534.6M
Q2 25
$3.0B
$495.0M
Q1 25
$3.0B
$500.8M
Q4 24
$3.3B
$377.0M
Q3 24
$3.4B
$376.3M
Q2 24
$3.0B
$376.8M
Debt / Equity
AAT
AAT
TARS
TARS
Q1 26
Q4 25
1.48×
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
1.72×
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AAT
AAT
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
14.5%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AAT
AAT
TARS
TARS
Q1 26
Q4 25
$167.1M
$19.3M
Q3 25
$40.5M
$18.3M
Q2 25
$49.2M
$-29.4M
Q1 25
$36.9M
$-20.7M
Q4 24
$207.1M
$-22.2M
Q3 24
$52.4M
$-8.7M
Q2 24
$59.3M
$-14.4M
Free Cash Flow
AAT
AAT
TARS
TARS
Q1 26
Q4 25
$94.9M
$13.0M
Q3 25
$23.1M
$16.3M
Q2 25
$28.4M
$-30.4M
Q1 25
$20.4M
$-21.2M
Q4 24
$136.9M
$-22.3M
Q3 24
$28.0M
$-8.9M
Q2 24
$43.6M
$-15.4M
FCF Margin
AAT
AAT
TARS
TARS
Q1 26
Q4 25
86.2%
8.6%
Q3 25
21.1%
13.8%
Q2 25
26.3%
-29.6%
Q1 25
18.8%
-27.1%
Q4 24
120.7%
-33.5%
Q3 24
22.8%
-18.6%
Q2 24
39.3%
-37.8%
Capex Intensity
AAT
AAT
TARS
TARS
Q1 26
14.5%
Q4 25
65.6%
4.2%
Q3 25
15.9%
1.6%
Q2 25
19.3%
1.0%
Q1 25
15.1%
0.8%
Q4 24
61.9%
0.1%
Q3 24
19.9%
0.6%
Q2 24
14.1%
2.5%
Cash Conversion
AAT
AAT
TARS
TARS
Q1 26
Q4 25
Q3 25
8.98×
Q2 25
9.01×
Q1 25
0.87×
Q4 24
Q3 24
3.15×
Q2 24
4.98×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AAT
AAT

Rental income$104.4M94%
Other$6.2M6%

TARS
TARS

Segment breakdown not available.

Related Comparisons